TOGETHER PHARMA LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 609.1 ILa | -1.88% |
|
+1.72% | +56.98% |
| 03-31 | Together Pharma Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Together Pharma Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 235 | 178.6 | 136 | 67.91 | 18.67 | 34.09 |
| Enterprise Value (EV) 1 | 243.1 | 197.4 | 187.5 | 146.2 | 73.45 | 85.3 |
| P/E ratio | -1.39 x | -9.15 x | 19.9 x | -4.77 x | -0.59 x | -7.9 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 12,221,465 x | 5,864,256 x | 597,843 x | 374,565 x |
| EV / Revenue | - | - | 16,847,610 x | 12,623,086 x | 2,352,102 x | 937,286 x |
| EV / EBITDA | -67.2 x | -14.3 x | 9.26 x | -26.7 x | -5.11 x | 3.09 x |
| EV / FCF | - | -31,289,246 x | -5,494,692 x | -3,795,808 x | 2,513,126 x | 5,027,440 x |
| FCF Yield | - | -0% | -0% | -0% | 0% | 0% |
| Price to Book | -7.9 x | -16.4 x | 16.4 x | 3.82 x | -51.1 x | -4.37 x |
| Nbr of stocks (in thousands) | 4,656 | 5,568 | 5,595 | 6,395 | 7,528 | 8,785 |
| Reference price 2 | 50.46 | 32.08 | 24.31 | 10.62 | 2.480 | 3.880 |
| Announcement Date | 18/03/19 | 31/03/20 | 24/03/21 | 31/03/22 | 30/03/23 | 31/03/24 |
1ILS in Million2ILS
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 11.13 | 11.58 | 31.23 | 91.01 |
| EBITDA 1 | -3.618 | -13.76 | 20.24 | -5.476 | -14.37 | 27.62 |
| EBIT 1 | -3.704 | -15.18 | 16.63 | -10.8 | -19.77 | 22.09 |
| Operating Margin | - | - | 149.42% | -93.21% | -63.31% | 24.28% |
| Earnings before Tax (EBT) 1 | -149.9 | -16.66 | 14.16 | -15.12 | -36.33 | 1.539 |
| Net income 1 | -149.9 | -15.28 | 7.152 | -13.78 | -33.52 | -4.316 |
| Net margin | - | - | 64.26% | -118.95% | -107.35% | -4.74% |
| EPS 2 | -36.20 | -3.508 | 1.219 | -2.228 | -4.180 | -0.4913 |
| Free Cash Flow | - | -6.309 | -34.13 | -38.51 | 29.23 | 16.97 |
| FCF margin | - | - | -306.62% | -332.55% | 93.59% | 18.64% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 61.44% |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 18/03/19 | 31/03/20 | 24/03/21 | 31/03/22 | 30/03/23 | 31/03/24 |
1ILS in Million2ILS
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 8.11 | 18.8 | 51.5 | 78.3 | 54.8 | 51.2 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -2.242 x | -1.364 x | 2.544 x | -14.29 x | -3.813 x | 1.854 x |
| Free Cash Flow | - | -6.31 | -34.1 | -38.5 | 29.2 | 17 |
| ROE (net income / shareholders' equity) | 1,032% | 80% | 1,175% | -74.8% | -247% | -1,076% |
| ROA (Net income/ Total Assets) | -21.9% | -21.4% | 10.8% | -4.75% | -8.57% | 10.3% |
| Assets 1 | 684.3 | 71.23 | 66.43 | 289.8 | 391.3 | -41.94 |
| Book Value Per Share 2 | -6.380 | -1.950 | 1.480 | 2.780 | -0.0500 | -0.8900 |
| Cash Flow per Share 2 | 0.0500 | 0.2000 | 1.030 | 0.9600 | 0.6000 | 0.4100 |
| Capex 1 | 3.89 | 8.05 | 13.8 | 1.53 | 0.33 | 0.87 |
| Capex / Sales | - | - | 123.56% | 13.21% | 1.07% | 0.95% |
| Announcement Date | 18/03/19 | 31/03/20 | 24/03/21 | 31/03/22 | 30/03/23 | 31/03/24 |
1ILS in Million2ILS
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +56.98% | 14.36M | |
| +24.98% | 9.22B | |
| -12.83% | 5.5B | |
| -12.36% | 1.98B | |
| -13.99% | 966M | |
| -16.70% | 747M | |
| -0.37% | 729M | |
| +14.15% | 247M | |
| -44.54% | 215M | |
| +3.17% | 191M |
- Stock Market
- Equities
- TGTR Stock
- Financials Together Pharma Ltd
